Baird raised the firm’s price target on Crinetics (CRNX) to $62 from $58 and keeps an Outperform rating on the shares. The firm updated its model following the Palsonify approval with a strong label and better than expected pricing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Buy Rating for Crinetics Pharmaceuticals Driven by FDA Approval and Strategic Market Positioning of Palsonify
- Crinetics Pharmaceuticals Gains FDA Approval for PALSONIFY
- Crinetics price target raised to $143 from $86 at Citizens JMP
- Crinetics announces FDA approval of PALSONIFY
- Crinetics Pharmaceuticals trading halted, news pending